HOWL
|Werewolf Therapeutics Inc
NASDAQ
USD 1.23
-0.08|-6.11%
Current Price
USD 1.23
Change
USD -0.08 (-6.11%)
P/E Ratio
Dividend Yield
Market Cap
54.75M
Volume
624,223
Open
USD 1.31
Previous Close
USD 1.31
52-Week High
USD 5.73
52-Week Low
USD 0.59
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Daniel J. Hicklin Ph.D.
Employees:46
Headquarters:Watertown, USA
Website:werewolftx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions